CYCN - Company ID 0001755237
The table below shows Cyclerion Therapeutics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $2.07M | $2.00M | $0.00 | $297.00K | $3.94M | $2.30M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $959.00K | $286.00K | $1.51M | $5.98M | $37.64M | $56.41M |
| SG&A |
Cyclerion Therapeutics, Inc. reported annual revenue of $2.07M for fiscal year 2025. That is up 3.7% from $2.00M in fiscal 2024. Over the 7 fiscal years shown, annual revenue declined from $4.51M (FY 2019) to $2.07M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $6.09M |
| $5.34M |
| $8.13M |
| $12.86M |
| $20.62M |
| $28.82M |
| Operating income | -$4.97M | -$3.63M | -$12.95M | -$18.54M | -$55.20M | -$81.27M |
| Income tax | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$3.53M | -$3.06M | -$5.26M | -$44.08M | -$51.65M | -$77.80M |
| EPS (diluted) | -$1.11 | -$1.21 | -$2.25 | -$20.28 | -$1.32 | - |